NAD IV therapy, subcutaneous NAD⁺ injections and oral NAD⁺ precursors are not three versions of the same treatment. They differ in bioavailability, dose ceiling, session time and the strength of the human evidence behind them. Intravenous infusion delivers the largest dose in a single session and bypasses the gut entirely. Oral precursors such as NMN and NR carry the broadest randomised trial data. The right route depends on your clinical goal, your tolerance and what your baseline testing shows.
What NAD⁺ actually does inside the cell
The job NAD⁺ does is an unglamorous one. Reactions all over your cells need electrons moved from one place to another, and NAD⁺ is the thing doing the moving, which is why calling it a fuel misleads people. It behaves more like a shuttle, picking up a load, dropping it somewhere else, going back for the next. Keep that shuttle running and your mitochondria can turn what you eat into ATP, and ATP is the form your cells will actually spend.
The second role is regulatory, and it is the one that matters for ageing. NAD⁺ is consumed as a substrate by sirtuins, which influence gene expression and mitochondrial maintenance, and by PARPs, which repair damaged DNA. Covarrubias and colleagues set out this dual role in a 2021 review in Nature Reviews Molecular Cell Biology. Every DNA repair event costs NAD⁺, as does every inflammatory signal handled by CD38, a third NAD⁺-consuming enzyme on immune cells.
Demand therefore rises exactly when supply is under pressure. Poor sleep, high alcohol intake, chronic inflammation, heavy training loads and metabolic stress all increase NAD⁺ turnover. That is the mechanism behind most of the claimed NAD⁺ benefits you will see advertised. It is a reasonable mechanism, and a plausible mechanism is not a proven clinical outcome. The rest of this article separates the two.
Why NAD⁺ declines with age
Very little of your NAD⁺ is made from scratch. Most of it comes back round through the salvage pathway, which rebuilds the coenzyme from the nicotinamide left behind when it breaks down. With age, two things seem to shift at once: salvage gets less efficient, while consumption climbs as CD38 and PARP activity rise on the back of low-grade inflammation and accumulated DNA damage.
How big that decline is depends on which tissue you look at and which study you read, and the assays used to measure it have not been standardised yet. Nobody has settled whether falling NAD⁺ drives age-related dysfunction or simply keeps it company. We treat it as a variable worth measuring and potentially modifying, rather than a proven cause of ageing.
NAD⁺, NADH, NMN and NR: what the names mean
Supplement bottle labels are the biggest source of confusion in this category. The difference between NAD⁺ and NADH is oxidation state: same molecule, different electron load. NMN and NR are not NAD⁺ at all. They are smaller precursor molecules your body converts into it.
| Molecule | What it is | Route into NAD⁺ |
|---|---|---|
| NAD⁺ | The oxidised coenzyme, ready to accept electrons | Already the active form |
| NADH | The reduced form, carrying electrons | Recycled back to NAD⁺ in metabolism |
| NMN (nicotinamide mononucleotide) | A precursor, one step from NAD⁺ | Converted via the salvage pathway |
| NR (nicotinamide riboside) | A precursor, one step before NMN | Phosphorylated to NMN, then to NAD⁺ |
The bioavailability problem: why the delivery route changes the outcome
How much of a dose actually arrives where it is needed? That is bioavailability, and with NAD⁺ the molecule itself complicates the answer. It is big, and it carries charge. Nikiforov and colleagues showed back in 2011 that human cells will not take it up whole, since it gets broken into smaller permeable pieces outside the cell before anything crosses. Swallowing it adds a second obstacle, because the gut wall and the liver both work on it during the trip. Precursors cope with all that far better, which is why you will struggle to find a serious oral product containing NAD⁺ rather than NMN or NR.
Then there is the gap between blood and cell, which tends to go unmentioned. Your plasma level rising is not the same event as your cells receiving more. Saqr and colleagues measured both and put plasma at roughly 500 times below the concentration inside peripheral blood mononuclear cells. Whoever designed the RENEWAL-NAD⁺ trial (ClinicalTrials.gov NCT07336836) evidently agrees, since intracellular and extracellular measurement is written into the primary objective on the grounds that systemic levels may not reflect delivery. Encouraging bloods, then. Not proof.
NAD⁺ IV therapy: dose, infusion rate and session length
An NAD infusion puts NAD⁺ straight into a vein, skipping gut conversion and first-pass metabolism altogether. That is why the intravenous route allows a larger single dose than any other.
Session times quoted across Sydney clinics range from about half an hour to four hours for the same molecule. If you have been shopping around, you have probably noticed that and wondered which one is right. Both can be, because the time is set by tolerance rather than by the bag.
The published numbers are all over the place, which turns out to be reassuring once you see why. Grant's team, writing up a 2019 pilot in Frontiers in Aging Neuroscience, ran a controlled six-hour infusion and watched plasma NAD⁺ do nothing at all for two hours before it started climbing, and it was still going up when they stopped at six. Reyna and colleagues were looking at something else entirely in Frontiers in Aging in 2026: commercial infusions, clients controlling their own flow rate, average NAD⁺ session around 97 minutes as against 37 for the precursor NR. Six people in each group, mind, so it hints at the shape of things rather than giving you a figure to schedule around.
Same molecule, similar nominal dose, and yet the time in the chair differs enormously. That spread reflects how much individual tolerance varies, which is the reason rate is managed person by person.
Why the drip runs slowly
Run a NAD⁺ infusion in fast and most people notice. Chest pressure, flushing, nausea, cramping in the abdomen, a racing heart, an odd tightness in the throat, sometimes a wave of anxiety. In the Reyna review, all six participants in the NAD⁺ IV group reported moderate to severe symptoms of that kind while the infusion ran, and all of them settled as soon as it finished.
The likely mechanism matters. Extracellular NAD⁺ normally sits at very low concentrations, and at high concentrations it appears to act as an inflammatory signal rather than a nutrient. Drive the extracellular level up fast and you are provoking that response.
So the drip runs slowly because rate, rather than total dose, is what drives the discomfort. Slowing the infusion is the usual response when someone reacts, and titrating gently from the outset heads off most of it in the first place. Wherever you have an infusion, it is reasonable to ask how the rate is set and how it will be adjusted if you react.
What a prescriber-led infusion protocol involves
Here, NAD⁺ for infusion or injection has to be compounded and it has to be prescribed, which puts it in a doctor's hands rather than on a list you pick from. The TGA does not approve compounded medicines one product at a time. It regulates the way they are supplied, and the practical effect of that is to leave clinical responsibility sitting with the prescriber.
Sequence is not incidental here. A consultation and a proper history have to come before anything else, partly because the exclusion criteria only mean something once somebody knows your background, and the baseline bloods follow on from that. The dose decision comes after all of it, then gets adjusted during the session itself, since how you respond on the day tells a prescriber more than any schedule could. At the end there is a written review, and that is where the call gets made on whether your next session stays as it is, changes, or is not worth booking.
Unglamorous, all of it. It is also the part that makes the treatment yours rather than generic.
Subcutaneous and intramuscular NAD⁺ injections
Injections go under the skin or into muscle, in a much smaller volume. What you give up is the dose ceiling, and it drops a long way. What you get back is a session measured in minutes, which counts for something if long infusions are not realistic for your week. The catch is that smaller doses tend to mean more of them. Expect a local reaction as well: stinging on the way in, some redness, a small lump, and a tender spot for a day or two.
Two things deserve a direct answer here.
First, dosage charts. Searches for a standard NAD⁺ injection dosage chart are common, and you will find plenty online. Biogenix does not publish one, and the reason is clinical rather than evasive. Appropriate dosing depends on body weight, renal and hepatic function, current medicines, tolerance at previous sessions and the goal of treatment. A chart cannot see any of that.
Second, supply. Injectable NAD⁺ sold through offshore websites and social media sits outside the Australian regulatory system. The TGA has issued guidance on unapproved injectable products of this kind, noting they have not been assessed for safety, quality or effectiveness. Sterility and ingredient grade are real concerns for anything intended for injection. Prescription and supply through a compounding pharmacy on a doctor's order is the lawful pathway.
Oral NAD⁺, NMN and NR: what the randomised trials show
It is worth being specific here.
Christen and colleagues published the first direct head-to-head human comparison of the three main precursors in Nature Metabolism, a randomised, open-label, placebo-controlled study of 65 healthy adults over 14 days. NR and NMN each roughly doubled circulating NAD⁺, with no significant difference between them. Plain nicotinamide produced only a brief rise about an hour in, with nothing sustained behind it. The study also found the gut microbiome plays a larger part in converting these precursors than previously assumed.
So oral precursors do raise the biomarker. Now the harder finding.
A systematic review with meta-analysis in Critical Reviews in Food Science and Nutrition pooled 12 randomised controlled trials covering 513 participants taking oral NMN. Blood NAD⁺ rose significantly. Most clinically relevant outcomes, including fasting glucose and lipid measures, did not differ from control. The authors noted risk-of-bias concerns across every included study and concluded the benefits of NMN may have been overstated in the field. A second meta-analysis in Current Diabetes Reports reached the same conclusion across eight trials, though it draws on an overlapping set of studies rather than an independent one. Muscle and physical-function reviews are similarly equivocal: Freeberg and colleagues, reviewing the field in the Journals of Gerontology in 2023, reported that multiple randomised trials had shown no effect of NR on insulin sensitivity, energy expenditure or exercise capacity.
Then there are the liposomal formulations, where the molecule sits inside a lipid shell meant to help it absorb. Plausible enough as chemistry. The trouble is that human data on liposomal NAD⁺ specifically remains thin on the ground, which makes it a hypothesis about formulation rather than an advantage anybody has demonstrated. Patches are on shakier ground still, since intact skin is a genuine barrier to something this large and this charged, and we have not seen a published human trial where patches shifted NAD⁺ by an amount worth mentioning. So if patches keep coming up in your search for the best NAD⁺ supplement in Australia, the evidence simply has not arrived.
Where does that leave oral precursors? They are a sensible maintenance strategy with solid evidence behind the biomarker and much less behind the clinical outcome, which is not the same as saying they do nothing. It is why we tend to treat an NAD supplement purchase in Australia as one layer of maintenance rather than the intervention on its own.
NAD⁺ delivery routes compared
Read this table as a summary of trade-offs, not a ranking. The best route is the one matched to your goal, your tolerance and your baseline results.
| Route | Typical dosing pattern | Dose ceiling | Bypasses gut conversion | Human evidence | Best suited to |
|---|---|---|---|---|---|
| IV infusion | Course of sessions, 1 to 4 hours each | Highest | Yes | Small trials, pharmacokinetic and tolerability data | Rapid loading under supervision |
| Subcutaneous injection | Frequent short sessions, minutes each | Moderate | Yes | Limited published data | Maintenance between infusions |
| Oral NMN or NR | Daily, ongoing | Low to moderate | No | Strongest randomised data for the biomarker | Long-term maintenance |
| Liposomal oral NAD⁺ | Daily, ongoing | Low | Partially | Minimal product-specific evidence | Trial of oral tolerance |
| Transdermal patch | Daily, ongoing | Very low | Yes | No convincing human trials | Not clinically supported |
How to tell whether it is working
Feeling good after an infusion is not evidence. Infusions involve a litre of fluid, an hour or more of rest and a strong expectation of benefit, and all three produce real sensations on their own.
Before anything goes in, measure. Whole blood NAD⁺ can be assayed, though the assays still are not standardised, so treat any single number as one data point and nothing more. What surrounds it tells you more: full blood count, renal and hepatic function, inflammatory markers, metabolic and hormonal panels, iron, B12. Plenty of things cause fatigue, and a fair few of them cost less to fix than a course of infusions. That is what a full diagnostics workup is for.
You also have to decide what you are watching, and it should be whatever sent you looking in the first place, whether that is sleep, the four o'clock slump, how you pull up two days after a hard session, or something else entirely. Two or three of those is plenty. Write them down weekly, pick the repeat pathology date at the start rather than deciding later, and you will have something to compare against.
Methylation clocks and biological age testing sit on a different timescale altogether. They shift slowly, the measurement noise on them is real, and four weeks of anything tends to disappear into that noise, so they will not settle the question of whether a course did what you hoped. Worth knowing that the same limitation applies to cryotherapy and other recovery therapies.
Side effects, contraindications and the five questions to ask any Sydney clinic
Most adverse effects from an infusion are tied to rate and do not last: chest tightness, flushing, nausea, cramping and a faster heart rate. Turning the rate down eases them, and they stop when the infusion does. Injections behave differently, producing local reactions instead, usually stinging and tenderness at the site.
Caution in some cases, and in others a flat no. Pregnancy and breastfeeding. Active malignancy, or a recent history of it, unless your oncologist has had a say. Serious renal or hepatic impairment. Arrhythmia, or cardiovascular disease that is not stable. Any medicine list long enough to need an interaction check. Reading that as a self-test would be the wrong use of it, because the point of the list is that somebody assesses you individually. Bring the history and the medicines along to the consultation and let a doctor work through it with you.
If you are comparing providers, these five questions are worth asking:
1. Who prescribes the NAD⁺, and are they a medical practitioner who will see me?
2. How is my dose determined, and how is the infusion rate set and adjusted?
3. What bloods come first, and what would make you change the plan?
4. If something goes wrong mid-infusion, who is standing there and what do they do?
5. Who follows me up afterwards, and does that go in writing?
You should expect a clear answer to all five.
Why Choose Biogenix for NAD⁺ Therapy in Sydney
At Biogenix, NAD⁺ therapy is prescribed and reviewed by registered medical practitioners. It is not a menu item, and it is not delivered on a fixed protocol applied uniformly to everyone who walks in.
Our founder, Dr Dominik Schaffner, is a German-Australian medical practitioner registered in Australia and qualified in Germany and the EU. He holds German board certification in orthopaedic and musculoskeletal trauma surgery, and his work spans regenerative medicine, longevity medicine and biologics, including PRP, stem cells, exosomes, peptides, cartilage regeneration and tissue engineering.
Dr Jonathan Herald, Founding Partner, is an Orthopaedic and Trauma Surgeon (MBBS, MSpMed, FRACS (Orth), FAOrthA) with postgraduate training at the Mayo Clinic and Mount Sinai, New York. He brings more than 20 years of experience in shoulder, elbow and knee surgery, including the care of athletes competing at elite level across several sports. Our regenerative work sits inside orthopaedic and sports medicine practice rather than beside it. Our international associate partner, Prof. Dr Philip Schoettle, practises across Munich, Zurich and Dubai. We publish credentials for every clinician on our Our Doctors page.
We are stubborn about a few things here. Nobody writes a protocol before the diagnostics come back, and the dose belongs to the patient rather than to the bag, which means it moves mid-session when a session calls for it. Courses end with a review, written down, so what happens next is a decision somebody made rather than something that drifted.
Our clinic is at Bankstown, and patients travel to us from across South West Sydney, the Inner West and the Sydney CBD. On-site parking is available and we are a short walk from Bankstown station. Initial consultations can be conducted by telehealth if that is easier for you.
Biogenix, Suite 105, 17 Meredith St, Bankstown NSW 2200. Phone +61 2 9128 3480. Email info@biogenix.com.au.
Follow our work on Instagram, Facebook and LinkedIn.
To discuss whether NAD⁺ IV therapy in Sydney suits your situation, book a consultation with our medical team.
Frequently asked questions
How long does an NAD⁺ infusion take?
Most people are in the chair somewhere between one and four hours, though it is tolerance that decides rather than the booking sheet, and a first visit is worth allowing extra time for, since the rate has to come up slowly before anyone knows how you react to it.
How much does NAD⁺ IV therapy cost in Sydney?
Cost depends on the protocol your doctor prescribes, the number of sessions and whether diagnostics are included, so we do not publish a single figure. Final cost is confirmed at consultation, once there is an actual plan to price. If a price is quoted before anyone has assessed you, it is worth asking what dose and how many sessions that figure assumes.
How often should you get NAD⁺ infusions?
There is no universal schedule. Loading courses of several closely spaced sessions followed by less frequent maintenance are common in practice, but frequency should follow your baseline results, your response and your goal. Your prescriber sets the interval and reviews it rather than committing you to a package upfront.
Is NAD⁺ IV better than oral supplements?
Better at what, really. Infusion delivers a much larger dose and skips gut conversion, so circulating NAD⁺ rises more sharply. Oral NMN and NR have the stronger randomised evidence for holding blood NAD⁺ up over a period of weeks, although that has not reliably turned into changed clinical outcomes. Plenty of patients use both, for different jobs.
What are the side effects of NAD⁺ IV therapy?
The common effects are rate-related and temporary: chest pressure, flushing, nausea, abdominal cramping and a raised heart rate during the infusion. In the real-world review cited above, symptoms resolved immediately once the infusion finished. Slowing the rate is the standard response. Injections more often cause local stinging and site tenderness instead.
Does NAD⁺ IV therapy actually work?
It reliably raises NAD⁺ in the blood. Whether that produces durable clinical benefit is not yet settled, because the human trials are small, short and focused mostly on pharmacokinetics and tolerability rather than outcomes. That is why we measure baseline pathology, define what we are tracking and review the result instead of relying on how a session felt.
Further reading
- NAD⁺ Therapy and IV Drip Therapy at Biogenix
- Diagnostics and Screening: mapping your biology before treatment
- Regenerative Medicine at Biogenix
- Our Doctors
Medical references
1. Therapeutic Goods Administration. Compounded medicines. https://www.tga.gov.au/products/unapproved-therapeutic-goods/compounded-medicines
2. Therapeutic Goods Administration. What to know if you're prescribed an unapproved therapeutic good. https://www.tga.gov.au/news/blog/what-know-if-youre-prescribed-unapproved-therapeutic-good
3. Therapeutic Goods Administration. Understanding your responsibilities when importing, compounding and supplying unapproved peptide products. https://www.tga.gov.au/safety/safety-monitoring-and-information/safety-alerts/understanding-your-responsibilities-when-importing-compounding-and-supplying-unapproved-peptide-products
4. Christen S et al (2026), The differential impact of three different NAD⁺ boosters on circulatory NAD and microbial metabolism in humans. Nature Metabolism. https://www.nature.com/articles/s42255-025-01421-8
5. Zhang J, Poon ET, Wong SH, Efficacy of oral nicotinamide mononucleotide supplementation on glucose and lipid metabolism for adults: a systematic review with meta-analysis on randomised controlled trials. Critical Reviews in Food Science and Nutrition 2025;65(22):4382–4400 (online 2024). https://pubmed.ncbi.nlm.nih.gov/39116016/
6. Chen et al, Effects of nicotinamide mononucleotide on glucose and lipid metabolism in adults: a systematic review and meta-analysis of randomised controlled trials. Current Diabetes Reports 2024;25:1. https://link.springer.com/article/10.1007/s11892-024-01557-z
7. Freeberg KA, Udovich CC, Martens CR, Seals DR, Craighead DH, Dietary supplementation with NAD⁺-boosting compounds in humans: current knowledge and future directions. Journals of Gerontology: Series A 2023;78(12):2435. https://pmc.ncbi.nlm.nih.gov/articles/PMC10692436/
8. Reyna K et al (2026), Intravenous infusion of NAD⁺ versus nicotinamide riboside: a retrospective tolerability pilot study in a real-world setting. Frontiers in Aging 7:1652582. https://pmc.ncbi.nlm.nih.gov/articles/PMC12907335/
9. Grant R et al (2019), A pilot study investigating changes in the human plasma and urine NAD⁺ metabolome during a 6 hour intravenous infusion of NAD⁺. Frontiers in Aging Neuroscience. https://pmc.ncbi.nlm.nih.gov/articles/PMC6751327/
10. Nikiforov A, Dölle C, Niere M, Ziegler M, Pathways and subcellular compartmentation of NAD biosynthesis in human cells. Journal of Biological Chemistry 2011;286(24):21767–78. https://pubmed.ncbi.nlm.nih.gov/21504897/
11. Saqr A et al, Optimized protocol for quantification of extracellular nicotinamide adenine dinucleotide. Frontiers in Medicine 2023;10:1278641. https://www.frontiersin.org/journals/medicine/articles/10.3389/fmed.2023.1278641/full
12. RENEWAL-NAD⁺ trial record, ClinicalTrials.gov, NCT07336836. https://clinicaltrials.gov/study/NCT07336836
13. Covarrubias AJ, Perrone R, Grozio A, Verdin E, NAD⁺ metabolism and its roles in cellular processes during ageing. Nature Reviews Molecular Cell Biology 2021;22:119–141. https://pmc.ncbi.nlm.nih.gov/articles/PMC7963035/
This article is general information and not a substitute for individual medical advice. NAD⁺ for infusion or injection is a prescription decision made by a medical practitioner after assessment. Outcomes vary between individuals and cannot be guaranteed.